Brostallicin Clinical Trial for Myxoid Liposarcoma

Summary

This is a Phase II, multicenter, open-label clinical trial designed to determine the efficacy and safety of Brostallicin when administered once every 3 weeks in patients with myxoid liposarcoma with (12;16) translocation. The primary objective of this study is to determine the response rate following Brostallicin administration.

Timeline

Start

2007-08

Primary completion

2008-10

Completion

2010-06

Drugs

Indications